Overview
- The lawsuit covers Unicycive securities purchased between March 29, 2024 and June 27, 2025.
- The complaint claims the company overstated its manufacturing compliance readiness and the regulatory outlook for its OLC new drug application.
- On June 10, 2025, Unicycive disclosed FDA-identified cGMP deficiencies at a third-party subcontractor, and the stock fell about 40.9%.
- On June 30, 2025, the company reported an FDA Complete Response Letter citing those deficiencies, and shares dropped roughly 29.9%.
- Multiple national firms, including Rosen, Faruqi & Faruqi, and Levi & Korsinsky, are soliciting class members, and no class has been certified.